Mark Lebwohl, MD, addressed a common clinical dilemma: selecting appropriate treatment regimens for patients with psoriasis amidst an expanding array of biologics and small-molecule inhibitors. His presentation emphasized the integration of therapeutic strategies tailored to disease severity, comorbidities, and patient preferences. He discussed vaccine management for patients on systemic therapies, perioperative considerations for immunomodulators, and obesity interventions using GLP-1 receptor agonists, which not only support weight loss but also improve psoriasis outcomes. Short-term biologics were highlighted as effective options for guttate psoriasis, while rapid interventions for generalized pustular psoriasis, including IL-36 inhibitors, were underscored as critical to mitigating severe disease progression.

A key focus was the utility of emerging therapies, such as risankizumab and bimekizumab, in achieving high clearance rates even in challenging cases like scalp and nail psoriasis. Dr Lebwohl also explored the management of refractory “mild” psoriasis, advocating for an individualized approach to care that improves patient-reported outcomes, including quality of life. His comprehensive discussion provided actionable insights into optimizing treatment plans to address both common and complex scenarios in psoriasis care.